Synthetic Antigen Constructs Against Campylobacter Jejuni

Patent metadata

Field	Value
Publication number	US-2016144017-A1
Application number	US-201514933793-A
Country	US
Kind code	A1
Filing date	Nov 5, 2015
Priority date	Nov 5, 2014
Publication date	May 26, 2016
Grant date	—

Abstract

The invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni ( C. jejuni ) in a subject comprising one or more monosaccharides comprising one or more MeOPN moieties. Specifically, the invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni ( C. jejuni ) in a subject comprising one or more MeOPN→6 Gal monosaccharides. The invention also relates to compositions comprising the immunogenic synthetic constructs and methods of inducing an immune response against C. jejuni in a subject comprising administering the immunogenic synthetic constructs, and/or compositions comprising the immunogenic synthetic construct, to the subject.

First claim

1 . An immunogenic synthetic construct capable of inducing an immune response against Campylobacter jejuni ( C. jejuni ) in a subject, wherein said immunogenic synthetic construct comprises one or more monosaccharides comprising one or more O-methyl phosphoramidate (MeOPN) moieties.

2 . The immunogenic synthetic construct of claim 1 wherein said immunogenic synthetic construct comprises one or more MeOPN→6 Gal monosaccharides.

3 . The immunogenic synthetic construct of claim 2 wherein said immunogenic synthetic construct is conjugated to a carrier protein.

4 . The immunogenic synthetic construct of claim 3 wherein the carrier protein contains at least one T-cell epitope.

5 . The immunogenic synthetic construct of claim 4 wherein the carrier protein is CRM 197 .

6 . The immunogenic synthetic construct of claim 1 wherein the subject is a human.

7 . A composition comprising the immunogenic synthetic construct of claim 1 .

8 . The composition of claim 7 wherein the composition is a pharmaceutical composition.

9 . The pharmaceutical composition of claim 8 wherein said pharmaceutical composition is a vaccine formulation.

10 . The vaccine formulation of claim 9 wherein the formulation further comprises one or more adjuvants.

11 . The vaccine formulation of claim 10 wherein the adjuvant is selected from the group consisting of toll-like receptor ligands, aluminum phosphate, aluminum hydroxide, monophosphoryl lipid A, liposomes, and derivatives and combinations thereof.

12 . The composition of claim 7 wherein the composition further comprises one or more additional immunoregulatory agents.

13 . The composition of claim 12 wherein the immunoregulatory agent is a substance selected from the group consisting of antigens of one or more strains of C. jejuni , antigens of ETEC, Shigella lipopolysaccharide structures, and unconjugated carrier proteins.

14 . The composition of claim 7 wherein the subject is a human.

15 . (canceled)

16 . A method of inducing an immune response against C. jejuni in a subject comprising administering to the subject an effective amount of the immunogenic synthetic construct of claim 1 .

17 . The method of claim 16 wherein the subject is human.

18 . A method of inducing an immune response against C. jejuni in a subject comprising administering to the subject an effective amount of the composition of claim 7 .

19 . The method of claim 18 wherein the subject is human.

20 . A method of inducing an immune response against C. jejuni in a subject comprising administering to the subject an effective amount of the composition of claim 8 .

21 . The method of claim 20 wherein said subject is a human.

22 . A method of inducing an immune response against C. jejuni in a subject, said method comprising
(a.) administering to the subject an effective amount of the immunogenic synthetic construct of claim 1 ; and (b.) optionally administering to the subject one or more boosting doses of the immunogenic synthetic construct administered in step (a).

23 . The method of claim 22 wherein the effective amount administered in step (a) is from about 0.1 μg to about 10 mg of the immunogenic synthetic construct.

24 . The method of claim 22 wherein said method further comprises administering an adjuvant with the construct in step (a) and/or step (b).

25 . A method of inducing an immune response against C. jejuni in a subject, said method comprising
(a). administering to the subject an effective amount of the composition of claim 8 ; and (b). optionally administering to the subject one or more boosting doses of the composition administered in step (a).

26 . The method of claim 25 wherein the effective amount administered in step (a) is from about 0.1 μg to about 10 mg of immunogenic synthetic construct.

27 . The method of claim 25 wherein said method further comprises administering an adjuvant with the construct in step (a) and/or step (b).

28 .- 36 . (canceled)

37 . The method of claim 20 wherein the composition is a vaccine formulation.

38 . The method of claim 25 wherein the composition is a vaccine formulation.

Assignees

• Guerry Patricia
• Monteiro Mario Artur
• Jiao Yuening
• Us Navy

Inventors

• Guerry Patricia
• Monteiro Mario Artur
• Jiao Yuening

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P1/12

  Antidiarrhoeals · CPC title